AncaSt

Nephrology Specialist, Assistant lecturer University of Medicine and Pharmacy Gr.T.Popa

[AncaSt @AncaSt13]

Let's goooooo #ERA26 ✨

[AncaSt @AncaSt13]

Short detour in Edinburgh before #ERA2026
@AgavriloaeiB

[AncaSt @AncaSt13]

Well, I will now use my bragging rights ✨

[AncaSt @AncaSt13]

Plant-based diets in CKD - doable?

[ERA - European Renal Association @ERAkidney]

How does sustainable nutrition look like in the context of CKD?
Over time, there have been numerous recommendations regarding nutrition in CKD: but how is it sustainable? Check it out in one of the latest ERA e-seminars:
Speaker: Susi Knöller
Moderator: Wesley Visser
Panelist @G_ErtanDemirtas
Panelist: @maxtorreggiani

[AncaSt @AncaSt13]

Check out this amazing article!

[ERA - European Renal Association @ERAkidney]

🧵 1/9
As Nephrology Dialysis Transplantation @NDTsocial celebrates 40 years 🎉, a new editorial ✨ highlights how biological sex shapes CV benefits of exercise in CKD.
@VanAmaryllis @olgabalafa @anagarcp #WERA
Read the full article at 🔗https://t.co/gSlO0aFGNY
Read the thread for a sneak peek 👇👇 👇

[AncaSt @AncaSt13]

Time for ⚖️

[AncaSt @AncaSt13]

Are sglt2i good for everything, including ADPKD? Check it out

[ERA - European Renal Association @ERAkidney]

📣SGLT2 inhibition for patients with ADPKD – closing the evidence gap
👉 an @erakidney e-seminar of the ERA Journal Club

Speaker: @MuellerRom
Moderator: @willkidney , Parminder Judge
Panelist: Roslyn Simms

[AncaSt @AncaSt13]

The drug that keeps giving? Check it out in the next e-seminar!

[ERA - European Renal Association @ERAkidney]

💁‍♂️12/ Signing off, on behalf of #ERA social media team, Agavriloaei Bogdan @AgavriloaeiB
If you’re interested in knowing more about the topic, you can watch the whole seminar
https://t.co/0aP1jnMeC7

[ERA - European Renal Association @ERAkidney]

What should you consider when supervising a child on an adult dialysis unit? 🚸In this e-seminar Rumeyza Kazancioglu provides many practical advices.

🟢Moderator: @RukshanaShroff
🟢Panellists: Jerome Harambat and @LynseyStronach

[AncaSt @AncaSt13]

Can we use gene therapy in kidney disease? Check out the answers in the following e-seminar👇

[ERA - European Renal Association @ERAkidney]

Gene therapy in inherited kidney disease: are we there yet❓
Gene and RNA therapies aim to fix disease at its genetic cause, not just treat symptoms. For inherited kidney diseases, this raises a new question: are we finally close to real cures?
Speaker: @gdorval12
Moderator: Roman-Urlich Müller
Panellist: Eris Olinger
Panellist: Moin Saleem

[AncaSt @AncaSt13]

How can we really help our CKD patients? Check out the following e-seminar 👇

[ERA - European Renal Association @ERAkidney]

🧵 How do we REALLY slow CKD progression & prevent complications?
🎙️ Luca De Nicola | Moderated by Jeroen Kooman
👥 With Filipa Ferreira & Danilo Fliser

[AncaSt @AncaSt13]

An ever developing area of nephrology! Check out the e-seminar 👇👇👇

[ERA - European Renal Association @ERAkidney]

Interventional Nephrology: a beginner’s guide for young nephrologists
🧵🧶An ERA - YNP e-seminar

🎙️ @DrBarbaTeba & Marina Urrutia Jou | Moderated by @HDiniz_
👥 With Jakob Gubensek & Faeq Husain-Syed

[AncaSt @AncaSt13]

When the heart and kidneys malfunction

[ERA - European Renal Association @ERAkidney]

1/Worsening renal function and chronic heart failure: double trouble
An @erakidney e-seminar of EuReCa-M WG

Speaker: @LiffertVogt
Moderator: Shanmugakumar Chinnappa
Panelist: @VanAmaryllis
Panelist: @fiatridi
💊You give furosemide and full dose RAS blockage 👉creatinine rises

⚔️A classic cardio-renal crossover
👇👇Management dilemmas addressed in this seminar

[ERA - European Renal Association @ERAkidney]

ERA e-seminars🚨

Mineral and bone disorders in peritoneal dialysis patients

Addressing the complexities of bone health in PD patients is vital for improving long-term outcomes
🎙️ Luciano Pereira
⚖️ Juan Miguel Díaz Tocados
👥 Gaetano Alfano & Maria Jesus Lloret

[AncaSt @AncaSt13]

What is new in LUPUS NEPHRITIS? A comparative analysis of the three guidelines (KDIGO, EULAR, ACR): a must watch 👇

[ERA - European Renal Association @ERAkidney]

Lupus nephritis: what do new guidelines say?
How do the latest international guidelines reshape the diagnosis and management of lupus nephritis (LN)?
This e-seminar explores the most recent recommendations from EULAR, KDIGO, and ACR, highlighting key updates, clinical impact, and evidence-based therapeutic strategies to improve patient outcomes.
Speaker: Jacob Koopman
Speaker: @mxipell
Panelist: @smirioglu
Moderator/Panelist: Magda Osipyan

[AncaSt @AncaSt13]

How important are genetics in renal transplantation? Check it out in the following e-seminar @ERA26

[ERA - European Renal Association @ERAkidney]

/1 Genetics in the Transplant Clinic

The collaborative seminar between G&K and DESCaRTEs highlighted the many ways in which genetics 🧬 can play a role in transplantation.

Speaker: Jan Halbritter 🇩🇪
Moderator: Emilie Cornec-LeGall 🇫🇷
Panellist: Christophe Mariat 🇫🇷, Maria Vanessa Perez Gomez @perezgomezmv 🇪🇸

[AncaSt @AncaSt13]

AKI - is it just a passing event? And is SGLT2i the drug that keeps on giving?
Check the following e-seminar for answer #ERA26
Great job on this, @AgavriloaeiB

[ERA - European Renal Association @ERAkidney]

Long-term cardiovascular complications following AKI 👉 an @erakidney e-seminar of the EuReCa - M Working group

Speaker: @MassyZiad
Moderator: Jalanta Malyszko

Panelist: @rolyathome Francesca Mallamaci

[AncaSt @AncaSt13]

Don't forget to submit your abstract for #ERA26
Deadline approaching 🕰️

[ERA - European Renal Association @ERAkidney]

🚨 Last week to submit your Abstract for #ERA26!
✨ Bring your passion, your vision, and your voice to the world stage
Don't miss the chance to challenge your thinking and submit your Abstract by January 28, 2026 👉 https://t.co/jsXpfkdVz9

[AncaSt @AncaSt13]

Obesity in CKD patients is becoming more prevalent, so we need to be on high alert 🚨
How can we help our patients? Check it out in this great 👇e-seminar @ERA26

[ERA - European Renal Association @ERAkidney]

🧶1/10 Do you treat CKD patients with Obesity?

🚨 Threadorial alert on Nutritional Management of Obesity and CKD. #ERA26 #nephrology

An @erakidney e-seminar by Prof. Allon Friedman🇺🇸

Moderator: Prof. Bengt Lindholm🇸🇪
Panellists: Prof. Maria Inês Barreto Silva🇧🇷 & Prof. Carolina Gracia-Iguacel🇪🇸

[Dr Rishabh Jain @DrRishabhOnco]

Noninferiority trials are NOT “no difference” trials. ⚠️
They can be statistically inferior… and still be called “noninferior.” 🤯

Here’s the simplest way to interpret any noninferiority trial like a pro 🧠👇

🧪 Noninferiority = “not substantially worse”
✅ Not about proving equality
✅ Not about “p>0.05 so same”

🎯 Key requirement:
The lower bound of the CI must stay above a pre-set margin (Δ)

📌 Why do we even accept this?
Because the new treatment may offer:
💊 less toxicity
💰 lower cost
🕒 easier delivery
😌 better QoL

But here’s the trap 👇
A treatment can be:
✅ Noninferior
AND
❌ Statistically worse than standard

🧠 Biggest mistake in medical Twitter discussions:
❌ “No significant difference → noninferior”
✅ Wrong. Noninferiority needs a margin + CI rule.

🔥 The authors recommend something CRITICAL:
✅ Use TWO margins, not one
1️⃣ Clinical noninferiority vs standard (Δclin)
2️⃣ Efficacy vs no treatment (Δeff)
Because even if you’re “close to standard”…
you might be no better than placebo 😬

📌 Also important:
⚠️ ITT analysis can be anti-conservative in noninferiority
Protocol violations make groups look similar → falsely supports NI

✅ Best practice: report BOTH
🧾 ITT + Per-protocol
and require NI in both

🧠 One-liner takeaway:
“Noninferior ≠ equivalent ≠ superior.”

📖 Full paper in comment ⬇️

#MedTwitter #OncoTwitter #ClinicalTrials #Biostatistics #EBM @OncoAlert @myesmo @esmo_open @asco